Bausch Health Reports Results Of Global Phase 3 RED-C Clinical Program; Trials Safe, But Did Not Meet Primary Endpoint

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the results of the global Phase 3 RED-C clinical program evaluating amorphous-rifaximin solid soluble dispersion (SSD) in adults with liver cirrhosis for the primary prevention of hepatic encephalopathy (HE). While safe and well-tolerated, both clinical trials did not meet the primary endpoint.

Bausch Health remains committed to bringing new treatments to patients across hepatology and other therapeutic areas.